
The US Food and Drug Administration has announced a sweeping new initiative aimed at speeding experimental drugs from the laboratory into human testing and ultimately toward approval, unveiling measures designed to cut development timelines, reduce information requirements, rely less on traditional animal testing, and accelerate the path to market















